Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Functional Assessment In TAVI: FAITAVI (FAITAVI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03360591
Recruitment Status : Recruiting
First Posted : December 4, 2017
Last Update Posted : May 12, 2021
Sponsor:
Information provided by (Responsible Party):
Flavio Ribichini, Universita di Verona

Brief Summary:

The aim of this study is to compare the clinical outcome of patients with severe aortic valve stenosis and associated significant coronary artery disease treated with TAVI and a percutaneous myocardial revascularization dictated according to two different strategies:

  1. the Angiographically-guided strategy;
  2. the Physiologically-guided strategy.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Aortic Valve Stenosis Device: Physiologically-guided strategy Not Applicable

Detailed Description:

Nowadays there are no clear recommendations about treatment of coronary in patients with severe aortic valve stenosis eligible for percutaneous valve replacement, and those available rely on a "common sense", class C, level of evidence. No randomized trials debride the skein about the best strategy of revascularization in this complex group of patients. In particular, it remains unclear whether it is preferable a preventive treatment or an ischemia-driven revascularization and, in addition, if it is safer and better for patient's health a simultaneous or a staged strategy.

The aim of this study is to compare the clinical outcome of patients with severe aortic valve stenosis and associated significant coronary artery disease treated with TAVI and a percutaneous myocardial revascularization dictated according to two different strategies.

The Angiographically-guided strategy is that of aiming the most complete degree of revascularization based on angiographic evaluation (stenting all coronary stenosis of major branches >2.5mm, with a %DS>50% as evaluated by visual estimation).

The Physiologically-guided strategy is that of treating only lesions with FFR ≤0.80, and leaving on optimal medical treatment lesions with FFR >0.80. The iFR values will be recorded in all patients, and verified in the core laboratory to allow a post-hoc analysis correlating the 0.80 FFR cut-off with different iFR cut-off values, according to recent observations and using the same study end-points.

Particular attention will be dedicated to the eventual occurrence of clinical events in patients deferred on the bases of FFR values >0.80 that show a discrepancy with positive (<0.89) iFR values to investigate the reliability of the FFR in the Aortic Stenosis setting.

Both groups will receive the same TAVI strategy and optimal medical therapy. The study is designed as randomized, prospective, multi.center, open label, experimental trial with medical device. After discharge patients will be contacted at 30 days, 6 - 12 and 24 months after the procedure to assess the general clinical status and at 12 months to assess the occurrence of events included in the primary and secondary endpoints. The duration of study participation is 24 months for enrolment, ad 24 months for final follow-up.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Functional Assessment In TAVI: FAITAVI
Actual Study Start Date : November 24, 2017
Estimated Primary Completion Date : February 2023
Estimated Study Completion Date : June 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Physiologically-guided strategy

Patients randomized in this group will undergo stenting of coronary lesions showing FFR values ≤0.80 only.

  • Lesions showing positive FFR measurements (<0.80) must be treated with PCI, before or after TAVI.
  • Lesions showing clearly negative values (FFR >0.80) will not be treated with PCI before TAVI, and repeated FFR and iFR measurements after TAVI are strongly recommended.
  • Lesions showing "borderline" FFR measurements before TAVI (FFR 0.80-0.83), should be measured again (both FFR and iFR) after TAVI, and the decision of treating of deferring treatment in a given lesion will be based on the FFR value obtained after TAVI.
  • In all cases iFR values will be recorded for a post hoc analysis and for validation of the study endpoints according to iFR values.
Device: Physiologically-guided strategy

The Angiographically-guided strategy is that of aiming the most complete degree of revascularization based on angiographic evaluation (stenting all coronary stenosis of major branches >2.5mm, with a % coronary stenosis>50% as evaluated by visual estimation.

The Physiologically-guided strategy is that of treating only lesions with FFR ≤0.80, and leaving on optimal medical treatment lesions with FFR >0.80. The iFR values will be recorded in all patients, and verified in the core laboratory to allow a post-hoc analysis correlating the 0.80 FFR cut-off with different iFR cut-off values, and using the same study end-points.

Particular attention will be dedicated to the eventual occurrence of clinical events in patients deferred on the bases of FFR values >0.80 that show a discrepancy with positive (<0.89) iFR values to investigate the reliability of the FFR in the aortic stenosis setting. Both groups will receive the same TAVI strategy and optimal medical therapy

Other Name: Angiographically-guided strategy

Angiographically-guided strategy
Patients allocated in this group will undergo stenting of all coronary stenosis ≥50% as assessed by visual estimation in vessels ≥2.5mm. PCI can be performed before in a previous procedure, or after TAVI, but always within one month, ± 5 days of the valve implantation.PCI in the group randomized to the angio-guided procedure can be performed therefore, either before or after valve implantation, in the same or in different procedures. Implantation of second-generation drug eluting stents (DES) in all interventions is advised, but not mandatory, and the brand of the stent is left to the operators and center's choice.
Device: Physiologically-guided strategy

The Angiographically-guided strategy is that of aiming the most complete degree of revascularization based on angiographic evaluation (stenting all coronary stenosis of major branches >2.5mm, with a % coronary stenosis>50% as evaluated by visual estimation.

The Physiologically-guided strategy is that of treating only lesions with FFR ≤0.80, and leaving on optimal medical treatment lesions with FFR >0.80. The iFR values will be recorded in all patients, and verified in the core laboratory to allow a post-hoc analysis correlating the 0.80 FFR cut-off with different iFR cut-off values, and using the same study end-points.

Particular attention will be dedicated to the eventual occurrence of clinical events in patients deferred on the bases of FFR values >0.80 that show a discrepancy with positive (<0.89) iFR values to investigate the reliability of the FFR in the aortic stenosis setting. Both groups will receive the same TAVI strategy and optimal medical therapy

Other Name: Angiographically-guided strategy




Primary Outcome Measures :
  1. Incidence of the treatment [ Time Frame: 12 months ]
    Composite of all-cause death, myocardial infarction, stroke, major bleeding and need for target vessel revascularization as adjudicated by the Clinical Event Committee


Secondary Outcome Measures :
  1. Safety endpoint [ Time Frame: 30 days ]
    Composite of all cause mortality, all strokes (disabling and not disabling), life threatening bleeding, AKI (stages 2 or 3, including need for dialysis), coronary artery obstruction requiring intervention, major vascular complication, valve related dysfunction requiring repeat procedure



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age > 18 years
  2. Written informed consent
  3. Diagnosis of severe native aortic valve disease with the indication to endovascular valve replacement given by Heart Team
  4. Diagnosis of at least one coronary stenosis >50% at angiography
  5. No specific pharmacologic treatment is required to enter the study

Exclusion Criteria:

  1. Age < 18 years
  2. Pregnancy
  3. Lack of informed consent
  4. Impaired left ventricular function
  5. Signs or symptoms of acute (unstable) myocardial ischemia
  6. Contraindication to adenosine administration (e.g., asthma, chronic obstructive pulmonary disease, heart rate <50 beats/min, and systolic blood pressure <90 mmHg)
  7. Reduced survival expectancy due to severe co-morbidities (<1 year)
  8. Impossibility to obtain follow-up information
  9. The lack of any of inclusion criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03360591


Contacts
Layout table for location contacts
Contact: Flavio L Ribichini, MD +39 045 812 ext 2320 flavio.ribichini@univr.it

Locations
Layout table for location information
Italy
Azienda Ospedaliera Universitaria Integrata Verona Recruiting
Verona, Italy, 37126
Contact: Flavio         
Sponsors and Collaborators
Universita di Verona
Layout table for additonal information
Responsible Party: Flavio Ribichini, Principal Investigator, Universita di Verona
ClinicalTrials.gov Identifier: NCT03360591    
Other Study ID Numbers: FAITAVI
First Posted: December 4, 2017    Key Record Dates
Last Update Posted: May 12, 2021
Last Verified: May 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Aortic Valve Stenosis
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Aortic Valve Disease
Heart Valve Diseases
Ventricular Outflow Obstruction